TRVI vs. CARA, PTI, VNDA, NUVB, LBPH, PLRX, MLYS, RNAC, HROW, and ZYME
Should you be buying Trevi Therapeutics stock or one of its competitors? The main competitors of Trevi Therapeutics include Cara Therapeutics (CARA), Proteostasis Therapeutics (PTI), Vanda Pharmaceuticals (VNDA), Nuvation Bio (NUVB), Longboard Pharmaceuticals (LBPH), Pliant Therapeutics (PLRX), Mineralys Therapeutics (MLYS), Cartesian Therapeutics (RNAC), Harrow (HROW), and Zymeworks (ZYME). These companies are all part of the "medical" sector.
Trevi Therapeutics (NASDAQ:TRVI) and Cara Therapeutics (NASDAQ:CARA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, community ranking, analyst recommendations, valuation and risk.
Trevi Therapeutics has higher earnings, but lower revenue than Cara Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Cara Therapeutics, indicating that it is currently the more affordable of the two stocks.
Trevi Therapeutics currently has a consensus price target of $8.50, indicating a potential upside of 248.36%. Cara Therapeutics has a consensus price target of $11.12, indicating a potential upside of 1,681.48%. Given Cara Therapeutics' higher probable upside, analysts clearly believe Cara Therapeutics is more favorable than Trevi Therapeutics.
Trevi Therapeutics has a net margin of 0.00% compared to Cara Therapeutics' net margin of -723.49%. Trevi Therapeutics' return on equity of -39.54% beat Cara Therapeutics' return on equity.
Cara Therapeutics received 589 more outperform votes than Trevi Therapeutics when rated by MarketBeat users. Likewise, 75.03% of users gave Cara Therapeutics an outperform vote while only 60.94% of users gave Trevi Therapeutics an outperform vote.
In the previous week, Trevi Therapeutics' average media sentiment score of 1.90 beat Cara Therapeutics' score of 0.00 indicating that Trevi Therapeutics is being referred to more favorably in the media.
Trevi Therapeutics has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, Cara Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.
95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 44.7% of Cara Therapeutics shares are owned by institutional investors. 24.4% of Trevi Therapeutics shares are owned by insiders. Comparatively, 3.1% of Cara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Trevi Therapeutics beats Cara Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Trevi Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Trevi Therapeutics Competitors List
Related Companies and Tools
